-
Unlocking the Code: New $28.6 Million Initiative Targets Protein Misfolding in Neurodegenerative Disease
A Bold Step Forward in Neuroscience In a groundbreaking development for medical research, a Stowers Institute for Medical Research scientist has been selected to join a high-stakes, $28.6 million research initiative. This ambitious project aims to decode the complex biological mechanisms behind protein misfolding, a process increasingly recognized as a key driver in devastating neurodegenerative…
-
NeuroSense’s PrimeC Shows Remarkable 65% Reduction in ALS Mortality Risk and Over 14-Month Survival Extension
NASDAQ: $NRSN NeuroSense Therapeutics Ltd., a biotechnology company concentrating on developing treatments for neurodegenerative conditions, has recently released compelling long-term survival data from its completed PARADIGM Phase 2b clinical trial assessing PrimeC for amyotrophic lateral sclerosis (ALS). This extended analysis confirms a clinically significant and statistically robust improvement in overall survival for patients treated with…